|Stage of funding:||Current|
Epic Sciences, Inc. is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic’s mission is to enable the rapid and non-invasive detection of genetic and molecular changes in cancer throughout a patient’s journey.
The company was founded on a powerful platform to identify and characterize rare cells, including CTCs. Epic's technology helps match patients to targeted therapies and monitor for drug resistance, so that the best treatment path can be chosen at every clinical decision point.
Today, Epic partners with leading pharmaceutical companies and major cancer centers around the world. Epic’s goal is to commercialize the Company's technology to increase the success rate of cancer drugs in clinical trials and improve patient outcomes by providing physicians real-time information to guide treatment choices.
NovaDigm Therapeutics, a company developing innovative immunotherapeutics and preventative vaccines for fungal and bacterial infections, today announced the initiation of a Phase 2a study evaluating NDV-3A for the reduction of Staphylococcus aureus (S. aureus) colonization in a high-risk population of military trainees. The study is being conducted with the Uniformed Services University of the Health Sciences (USU) and is enrolling U.S. Army Infantry trainees at Fort Benning, GA. NDV-3A is the company’s lead development candidate to potentially treat antimicrobial resistant fungal and bacterial pathogens.
12 April 2018
30 March 2018
Epic Sciences and Genomic Health Announce Favorable Draft Local Coverage Determination (LCD) on Medicare Coverage for Use of the Oncotype DX® AR-V7 Nucleus Detect™ Test in Patients with Metastatic Castration-Resistant Prostate Cancer
14 March 2018